The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Authors
Keywords
-
Journal
NATURE
Volume 615, Issue 7954, Pages 920-924
Publisher
Springer Science and Business Media LLC
Online
2023-03-16
DOI
10.1038/s41586-023-05812-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MEN1 mutations mediate clinical resistance to menin inhibition
- (2023) Florian Perner et al. NATURE
- Menin is necessary for long term maintenance of meningioma-1 driven leukemia
- (2021) Clara Libbrecht et al. LEUKEMIA
- Therapeutic implications of menin inhibition in acute leukemias
- (2021) Ghayas C. Issa et al. LEUKEMIA
- The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
- (2021) Emily B. Heikamp et al. BLOOD
- Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
- (2020) Hannah J. Uckelmann et al. SCIENCE
- Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis
- (2020) Kelly J. Norsworthy et al. CLINICAL CANCER RESEARCH
- Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition
- (2020) Margarita M. Dzama et al. BLOOD
- Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A
- (2020) Marius Bill et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
- (2019) Andrei V. Krivtsov et al. CANCER CELL
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
- (2016) M. W. M. Ku hn et al. Cancer Discovery
- How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia
- (2014) M. A. Sanz et al. BLOOD
- Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
- (2013) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- (2013) Francesco Lo-Coco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
- (2012) Jolanta Grembecka et al. Nature Chemical Biology
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
- (2009) David Grimwade et al. JOURNAL OF CLINICAL ONCOLOGY
- Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
- (2008) Jeffrey M. Skolnik et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now